Phaseline

Targets › SIRT1

SIRT1 (NAD-dependent protein deacetylase sirtuin-1): drug programs, companies and trials

2 programs from 2 companies in 2 trials: 2 Phase 2; Respiratory, Neurology; next expected readout Jan 2027.

NAD-dependent protein deacetylase that links transcriptional regulation directly to intracellular energetics and participates in the coordination of several separated cellular functions such as cell cycle, response to DNA damage, metabolism, apoptosis and autophagy. Can modulate chromatin function through deacetylation of histones and can promote alterations in the methylation of histones and DNA, leading to…. (UniProt, Q96EB6)

Open in Phaseline: the race on SIRT1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Cedars-Sinai Medical CenterNicotinamide riboside
NAD+ precursor; may enhance mitochondrial function and cellular stress responses
SIRT1Phase 2Idiopathic Pulmonary FibrosisJan 2027
Georgetown UniversityTrans-Resveratrol (JOTROL)
SIRT1 activator; stimulates mitochondrial biogenesis and mitochondrial dynamics via autoph
SIRT1Phase 2Parkinson's DiseaseJun 2028

Conditions

Idiopathic Pulmonary Fibrosis (1) Parkinson's Disease (1)

Modalities

small molecule (2)

Companies

Cedars-Sinai Medical Center (1) Georgetown University (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.